PROTAC Library - PROTAC® / BOC Sciences

Structure	Catalog	Product Name	E3 Ligase	Target	Inquiry
	BPL-202513	(E)-N-(2-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethyl)-2-(4-(4-oxo-4-(4-(2',5',6-trichloro-4-methoxy-[1,1'-biphenyl]-3-carbonyl)piperazin-1-yl)but-2-enoyl)piperazin-1-yl)acetamide	CRBN	KRAS G12C	Inquiry
Molecular Weight: 922.22 Molecular Formula: C43H43Cl3N8O9 Description: It is a KRas G12C-IN-3 and Pomalidomide-based PROTAC as an endogenous KRAS G12C degrader with potent anticancer activity.
	BPL-202514	(E)-N-(3-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)propyl)-2-(4-(4-oxo-4-(4-(2',5',6-trichloro-4-methoxy-[1,1'-biphenyl]-3-carbonyl)piperazin-1-yl)but-2-enoyl)piperazin-1-yl)acetamide	CRBN	KRAS G12C	Inquiry
Molecular Weight: 936.25 Molecular Formula: C44H45Cl3N8O9 Description: It is a KRas G12C-IN-3 and Pomalidomide-based PROTAC as an endogenous KRAS G12C degrader with potent anticancer activity.
	BPL-202515	(E)-N-(4-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)butyl)-2-(4-(4-oxo-4-(4-(2',5',6-trichloro-4-methoxy-[1,1'-biphenyl]-3-carbonyl)piperazin-1-yl)but-2-enoyl)piperazin-1-yl)acetamide	CRBN	KRAS G12C	Inquiry
Molecular Weight: 950.28 Molecular Formula: C45H47Cl3N8O9 Description: It is a KRas G12C-IN-3 and Pomalidomide-based PROTAC as an endogenous KRAS G12C degrader with potent anticancer activity.
	BPL-202516	(E)-N-(6-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)hexyl)-2-(4-(4-oxo-4-(4-(2',5',6-trichloro-4-methoxy-[1,1'-biphenyl]-3-carbonyl)piperazin-1-yl)but-2-enoyl)piperazin-1-yl)acetamide	CRBN	KRAS G12C	Inquiry
Molecular Weight: 978.33 Molecular Formula: C47H51Cl3N8O9 Description: It is a KRas G12C-IN-3 and Pomalidomide-based PROTAC as an endogenous KRAS G12C degrader with potent anticancer activity.
	BPL-202517	N-(17-(4-(3-Amino-5-(4-amino-4-methylpiperidin-1-yl)pyrazin-2-yl)-2,3-dichlorophenyl)-3,6,9,12,15-pentaoxaheptadecyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide	CRBN	SHP2	Inquiry
Molecular Weight: 929.86 Molecular Formula: C43H54Cl2N8O11 Description: It is a SHP2 PROTAC created by conjugating RMC-4550 with pomalidomide using a PEG linker. It is highly selective for SHP2, induces degradation of SHP2 in leukemic cells at submicromolar concentrations, inhibits MAPK signaling, and suppresses cancer cell growth.
	BPL-202518	N-(17-(3-(3-Amino-5-(4-amino-4-methylpiperidin-1-yl)pyrazin-2-yl)-4,5-dichlorophenyl)-3,6,9,12,15-pentaoxaheptadecyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide	CRBN	SHP2	Inquiry
Molecular Weight: 929.86 Molecular Formula: C43H54Cl2N8O11 Description: It is a SHP2 PROTAC created by conjugating RMC-4550 with pomalidomide using a PEG linker. It is highly selective for SHP2, induces degradation of SHP2 in leukemic cells at submicromolar concentrations, inhibits MAPK signaling, and suppresses cancer cell growth.
	BPL-202519	N-(17-(4-(3-Amino-5-(4-amino-4-methylpiperidin-1-yl)pyrazin-2-yl)-2,3-dichlorophenoxy)-3,6,9,12,15-pentaoxaheptadecyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide	CRBN	SHP2	Inquiry
Molecular Weight: 945.86 Molecular Formula: C43H54Cl2N8O12 Description: It is a SHP2 PROTAC created by conjugating RMC-4550 with pomalidomide using a PEG linker. It is highly selective for SHP2, induces degradation of SHP2 in leukemic cells at submicromolar concentrations, inhibits MAPK signaling, and suppresses cancer cell growth.
	BPL-202520	N-(17-(3-(3-Amino-5-(4-amino-4-methylpiperidin-1-yl)pyrazin-2-yl)-4,5-dichlorophenoxy)-3,6,9,12,15-pentaoxaheptadecyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide	CRBN	SHP2	Inquiry
Molecular Weight: 945.86 Molecular Formula: C43H54Cl2N8O12 Description: It is a SHP2 PROTAC created by conjugating RMC-4550 with pomalidomide using a PEG linker. It is highly selective for SHP2, induces degradation of SHP2 in leukemic cells at submicromolar concentrations, inhibits MAPK signaling, and suppresses cancer cell growth.
	BPL-202521	N-(2-(2-(2-(2-(4-(5-((3S,4S)-4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(hydroxymethyl)-3-methylpyrazin-2-yl)-2,3-dichlorophenoxy)ethoxy)ethoxy)ethoxy)ethyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide	CRBN	SHP2 SHP2 F285S	Inquiry
Molecular Weight: 942.85 Molecular Formula: C44H53Cl2N7O12 Description: It is a SHP2 PROTAC created by conjugating RMC-4550 with pomalidomide using a PEG linker. It is highly selective for SHP2, induces degradation of SHP2 in leukemic cells at submicromolar concentrations, inhibits MAPK signaling, and suppresses cancer cell growth.
	BPL-202522	N-(17-(4-(5-((3S,4S)-4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(hydroxymethyl)-3-methylpyrazin-2-yl)-2,3-dichlorophenoxy)-3,6,9,12,15-pentaoxaheptadecyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide	CRBN	SHP2 SHP2 F285S	Inquiry
Molecular Weight: 1030.96 Molecular Formula: C48H61Cl2N7O14 Description: It is a SHP2 PROTAC created by conjugating RMC-4550 with pomalidomide using a PEG linker. It is highly selective for SHP2, induces degradation of SHP2 in leukemic cells at submicromolar concentrations, inhibits MAPK signaling, and suppresses cancer cell growth.
	BPL-202523	N-(23-(4-(5-((3S,4S)-4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(hydroxymethyl)-3-methylpyrazin-2-yl)-2,3-dichlorophenoxy)-3,6,9,12,15,18,21-heptaoxatricosyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide	CRBN	SHP2 SHP2 F285S	Inquiry
Molecular Weight: 1119.06 Molecular Formula: C52H69Cl2N7O16 Description: It is a SHP2 PROTAC created by conjugating RMC-4550 with pomalidomide using a PEG linker. It is highly selective for SHP2, induces degradation of SHP2 in leukemic cells at submicromolar concentrations, inhibits MAPK signaling, and suppresses cancer cell growth.
	BPL-202524	MA055	VHL	Wee1	Inquiry
Molecular Weight: 985.23 Molecular Formula: C52H64N12O6S Description: It is a PROTAC using AZD1775 linked to the VHL ligand VH032. It induces the selective degradation of Wee1.
	BPL-202525	(2S,4R)-1-((S)-2-(4-(4-(4-(4-((2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-3-oxo-2,3-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)phenyl)piperazin-1-yl)butanamido)butanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide	VHL	Wee1	Inquiry
Molecular Weight: 1070.33 Molecular Formula: C56H71N13O7S Description: It is a PROTAC using AZD1775 linked to the VHL ligand VH032. It induces the selective degradation of Wee1.
	BPL-202526	(2S,4R)-1-((S)-2-(6-(4-(4-(4-((2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-3-oxo-2,3-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)phenyl)piperazin-1-yl)butanamido)hexanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide	VHL	Wee1	Inquiry
Molecular Weight: 1098.39 Molecular Formula: C58H75N13O7S Description: It is a PROTAC using AZD1775 linked to the VHL ligand VH032. It induces the selective degradation of Wee1.
	BPL-202527	(2S,4R)-1-((S)-2-(8-(4-(4-(4-((2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-3-oxo-2,3-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)phenyl)piperazin-1-yl)butanamido)octanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide	VHL	Wee1	Inquiry
Molecular Weight: 1126.44 Molecular Formula: C60H79N13O7S Description: It is a PROTAC using AZD1775 linked to the VHL ligand VH032. It induces the selective degradation of Wee1.
	BPL-202528	(2S,4R)-1-((S)-2-(11-(4-(4-(4-((2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-3-oxo-2,3-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)phenyl)piperazin-1-yl)butanamido)undecanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide	VHL	Wee1	Inquiry
Molecular Weight: 1168.52 Molecular Formula: C63H85N13O7S Description: It is a PROTAC using AZD1775 linked to the VHL ligand VH032. It induces the selective degradation of Wee1.
	BPL-202529	(2S,4R)-1-((S)-19-(4-(4-((2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-3-oxo-2,3-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)phenyl)piperazin-1-yl)-2-(tert-butyl)-4,16-dioxo-6,9,12-trioxa-3,15-diazanonadecanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide	VHL	Wee1	Inquiry
Molecular Weight: 1174.44 Molecular Formula: C60H79N13O10S Description: It is a PROTAC using AZD1775 linked to the VHL ligand VH032. It induces the selective degradation of Wee1.
	BPL-202530	(2S,4R)-1-((S)-23-(4-(4-((2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-3-oxo-2,3-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)phenyl)piperazin-1-yl)-2-(tert-butyl)-4,20-dioxo-7,10,13,16-tetraoxa-3,19-diazatricosanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide	VHL	Wee1	Inquiry
Molecular Weight: 1232.52 Molecular Formula: C63H85N13O11S Description: It is a PROTAC using AZD1775 linked to the VHL ligand VH032. It induces the selective degradation of Wee1.
	BPL-202531	4-(4-(4-((2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-3-oxo-2,3-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)phenyl)piperazin-1-yl)-N-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethyl)butanamide	CRBN	Wee1	Inquiry
Molecular Weight: 870.97 Molecular Formula: C45H50N12O7 Description: It is a PROTAC using AZD1775 linked to the CRBN ligand pomalidomide. It induces the selective degradation of Wee1.
	BPL-202532	4-(4-(4-((2-Allyl-1-(6-(2-hydroxypropan-2-yl)pyridin-2-yl)-3-oxo-2,3-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)phenyl)piperazin-1-yl)-N-(6-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)hexyl)butanamide	CRBN	Wee1	Inquiry
Molecular Weight: 927.08 Molecular Formula: C49H58N12O7 Description: It is a PROTAC using AZD1775 linked to the CRBN ligand pomalidomide. It induces the selective degradation of Wee1.